Browsing by Author Fabri, Milotka
Showing results 1 to 4 of 4
| Issue Date | Title | Author(s) |
|---|---|---|
| 1-Jan-2014 | Randomized comparison of Tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B | Fung S.; Kwan P.; Fabri, Milotka; Horban A.; Pelemis M.; Hann H.; Gurel S.; Caruntu F.; Flaherty J.; Massetto B.; Dinh P.; Corsa A.; Subramanian G.; McHutchison J.; Husa P.; Gane E. |
| 1-May-2019 | Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir + dasabuvir + ribavirin in the patients with genotype 1 chronic hepatitis c virus infection in serbia | Simonović Babić, Jasmina; Bojović, Ksenija; Fabri, Milotka; Cvejić, Tatjana; Svorcan, Petar; Nožić, Darko; Jovanović, Maja; Škrbić, Ranko; Stojiljković, M.; Mijailović, Ž. |
| 1-Jan-2017 | Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study | Fung S.; Kwan P.; Fabri, Milotka; Horban A.; Pelemis M.; Hann H.; Gurel S.; Caruntu F.; Flaherty J.; Massetto B.; Kim K.; Kitrinos K.; Subramanian G.; McHutchison J.; Yee L.; Elkhashab M.; Berg T.; Sporea I.; Yurdaydin C.; Husa P.; Jablkowski M.; Gane E. |
| 1-Jul-2019 | Validity of hepatitis B and hepatitis C case definitions | Dakic Z.; Duric P.; Fabri, Milotka; O'May F. |